CN115590810A - Segmented soluble microneedle solution, application, soluble microneedle and manufacturing method thereof - Google Patents
Segmented soluble microneedle solution, application, soluble microneedle and manufacturing method thereof Download PDFInfo
- Publication number
- CN115590810A CN115590810A CN202211137197.4A CN202211137197A CN115590810A CN 115590810 A CN115590810 A CN 115590810A CN 202211137197 A CN202211137197 A CN 202211137197A CN 115590810 A CN115590810 A CN 115590810A
- Authority
- CN
- China
- Prior art keywords
- microneedle
- soluble
- segmented
- solution
- soluble microneedle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 22
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims abstract description 67
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 38
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229930195725 Mannitol Natural products 0.000 claims abstract description 37
- 239000000594 mannitol Substances 0.000 claims abstract description 37
- 235000010355 mannitol Nutrition 0.000 claims abstract description 37
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960000502 poloxamer Drugs 0.000 claims abstract description 36
- 229920001983 poloxamer Polymers 0.000 claims abstract description 36
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940120503 dihydroxyacetone Drugs 0.000 claims abstract description 33
- 239000000758 substrate Substances 0.000 claims abstract description 26
- 238000001035 drying Methods 0.000 claims abstract description 20
- -1 fucoidin Chemical compound 0.000 claims abstract description 17
- 238000011049 filling Methods 0.000 claims description 14
- 229920000855 Fucoidan Polymers 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 40
- 230000011218 segmentation Effects 0.000 abstract description 7
- 238000013329 compounding Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 76
- 229940079593 drug Drugs 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000013271 transdermal drug delivery Methods 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108010033949 polytyrosine Proteins 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a sectional type soluble microneedle solution, application, a soluble microneedle and a manufacturing method thereof, wherein the sectional type soluble microneedle solution comprises the following components: GH. Histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water. The application refers to the application of the sectional soluble microneedle solution in preparing sectional soluble microneedles, the sectional soluble microneedles containing the sectional soluble microneedle solution and the manufacturing method of the sectional soluble microneedles. Compared with the prior art, the preparation method has the advantages that histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and GH are selected for compounding, the problem that the medicine diffuses to the microneedle substrate in the drying process of the sectional type microneedle is solved, the prepared microneedle point is obvious in segmentation, the medicine at the point is not diffused basically, accurate administration is achieved, the preparation time is shortened, and the production efficiency is improved.
Description
Technical Field
The invention relates to the technical field of microneedles, in particular to a segmented soluble microneedle solution, application, a soluble microneedle and a manufacturing method thereof.
Background
Soluble micro-needle, as a novel painless transdermal drug delivery technology, makes the medicine into micron-sized micro-needle array with enough strength, enhances the permeability of skin to active medicine, especially macromolecule active ingredient, and enables the medicine to directly penetrate the stratum corneum and directly reach the inside of the skin. The needle body material of the micro-needle is generally composed of soluble high molecular biological material, and in the preparation process, the soluble biological material is directly mixed with the medicine, so that the medicine exists in the needle body of the micro-needle. After the needle body of the micro-needle penetrates into the stratum corneum of the skin, the needle body of the soluble micro-needle is dissolved by the interstitial fluid of the skin, and the specific medicine mixed in the needle body of the micro-needle is gradually released into the skin, so that the purpose of administration is realized. The soluble microneedle has the advantages of hypodermic injection and traditional transdermal drug delivery, breaks through the limitation that the traditional transdermal patch can only conduct small-molecule drugs, and is an international research and development hotspot in the technical field of novel transdermal drug delivery.
At present, the common preparation method of the soluble drug micro-needle is to dissolve the drug in the related solvent to form the structure of the whole needle head to enter the skin, but the difference of the thickness of the horny layer of the skin is large due to the difference of the using position, the age of people and the skin state, and the difference of the pressing strength, the method and the like of a user, so that the precise quantitative transmission of the drug is difficult to realize, and the administration route of a plurality of dose-sensitive drugs cannot be changed. Sectional type soluble micropin ensures that the medicine is carried in the needle point part of needle body, forms the needle point medicine carrying gathering to can carry the medicine completely and get into skin, the effectual medicine that overcomes arouses because of skin thickness and pressing force degree difference is led into the efficiency deviation, realizes accurate dosing. To improve the efficiency of drug delivery and to precisely control the drug delivered dose, a step-and-pour method may be used to focus the drug at the needle tip. However, in the process of preparing the micro-needle, the drug is easy to diffuse to the water-soluble micro-needle substrate, and the drug encapsulation of the needle point is difficult to control.
Disclosure of Invention
In order to solve the technical problems, the invention provides a sectional type soluble microneedle solution, application, a soluble microneedle and a manufacturing method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a segmented soluble microneedle solution comprising the following components: GH. Histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water.
According to the weight percentage, the dosage of GH is 1.53% -15.23%, preferably 1.92-14.55%; most preferably 6.47%.
The dosage of the segmented soluble microneedle solution is 0.03-0.12% by weight, preferably 0.06-0.09% by weight; most preferably 0.08%.
The sectional type soluble microneedle solution comprises, by weight, 0.06-0.30% of poloxamer, preferably 0.10-0.27%; most preferably 0.19%.
The sectional type soluble microneedle solution comprises, by weight, 0.31-4.57% of mannitol, preferably 0.64-4.24%; most preferably 2.27%.
The sectional type soluble microneedle solution comprises, by weight, 0.15-0.61% of fucoidin, preferably 0.26-0.55%; most preferably 0.39%.
The sectional type soluble microneedle solution comprises, by weight, 6.12-18.27% of dihydroxyacetone, preferably 7.66-13.64%; most preferably 9.71%.
The sectional type soluble microneedle solution comprises, by weight, 60.90-91.80% of pure water, preferably 66.66-89.36%; most preferably 80.89%.
The technical effects of the invention can be realized by the above technical schemes, but in some preferred embodiments, the achieved technical effects are superior to other schemes.
For example: the dosage of the fucoidin is 0.26-0.55%; the using amount of the dihydroxyacetone is 7.66-13.64%; the specific components of the composition comprise, by weight, GH 1.92%, histidine 0.06%, poloxamer 0.10%, mannitol 0.64%, fucoidin 0.26%, dihydroxyacetone 7.66% and pure water 89.36%.
Most preferably, the segmented soluble microneedle solution comprises specific components of GH6.47%, histidine 0.08%, poloxamer 0.19%, mannitol 2.27%, fucoidan 0.39%, dihydroxyacetone 9.71% and pure water 80.89% in percentage by weight.
The invention also provides a preparation method of the segmented soluble microneedle solution, which comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming to obtain the sectional type soluble microneedle solution.
The invention also provides application of the segmented soluble microneedle solution in preparing segmented soluble microneedles.
The invention also provides a sectional type soluble microneedle which is prepared from the sectional type soluble microneedle solution.
The invention also provides a manufacturing method of the segmented soluble microneedle, which comprises the following steps:
s1, infusing the sectional type soluble microneedle solution into a microneedle mould to form a microneedle tip;
and S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, drying and demolding to obtain the microneedle substrate preparation.
Preferably, the perfusion method in steps S1 and S2 includes, but is not limited to, high pressure jetting, centrifugation, vacuum adsorption, or self-leveling.
Preferably, the microneedle substrate formulation described in step S2 is a dissolvable biodegradable material comprising at least one of polyester, PHA, PHBV, PHP, PHH, PHA-PEG, poly-4-hydroxy acid, poly-alpha-hydroxy acid, poly-beta-hydroxy acid, poly-4-hydroxybutyrate, poly-4-hydroxyvalerate, poly-4-hydroxyhexanoate, polyesteramide, polycaprolactone, polylactide, polyglycolide, PLGA, polydioxanone, polyorthoester, polyetherester, polyanhydride, glycolic acid-trimethylene carbonate copolymer, polyphosphate, polyphosphoester urethane, polyamino acid, polycyanoacrylate, polytrimethylene carbonate, polyiminocarbonate, polytyrosine carbonate, polycarbonate, polytyrosine arylester, povidone, polyalkylene ester, polyphosphocreatine, chitosan, dextran, polyvinyl alcohol, cellulose, heparin, sodium hyaluronate, alginic acid, inulin, starch and glycogen.
Preferably, the environmental conditions for forming the microneedle tip in step S1 are: the temperature is 20-28 ℃, and the relative humidity is 45-65%.
Preferably, the drying conditions in step S2 are: the temperature is 20-35 ℃, the relative humidity is 30-60%, and the drying time is more than 2 h; more preferably 20-30 deg.C, relative humidity of 40-50%, and drying time of 2 hr or more.
The beneficial effects of the invention are as follows:
according to the invention, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and GH are selected for compounding, so that the problem that a substrate solution is not dried and rapidly filled after the sectional type microneedle tip filling liquid is filled, and the drug diffuses to a microneedle substrate in the drying process of the microneedle is solved, the prepared microneedle tip is obvious in segmentation, the drug at the tip is not substantially diffused, the precise administration is realized, the preparation time is shortened, and the effectiveness efficiency is improved.
Drawings
Fig. 1 is a picture of segmented microneedles prepared in examples of the present invention and comparative examples.
In the figure, S1, S2, S3, S4, S5, S6 and S7 represent the pictures of the sectioned microneedles prepared in examples 1 to 7, respectively, and D1, D2, D3 and D4 represent the pictures of the sectioned microneedles prepared in comparative examples 1 to 4, respectively.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not to be limited to the specific embodiments described below; it is also to be understood that the terminology used in the examples herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any number between the two endpoints are optional unless otherwise specified in the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The sources of the raw materials used in the present invention are not limited, and the raw materials used in the present invention are all those commonly available in the art unless otherwise specified. GH (Uniprot: P01241), histidine (CAS: 71-00-1), poloxamer 188 (CAS: 9003-11-6), mannitol (CAS: 69-65-8), fucoidan (CAS: 9072-19-9) and dihydroxyacetone (CAS: 96-26-4), wherein the base preparation is one or more of sodium hyaluronate, lactide-glycolide copolymer, povidone or polyvinyl alcohol.
Example 1
A segmented soluble microneedle solution comprises the following components in percentage by weight: GH1.53%, histidine 0.03%, poloxamer 0.06%, mannitol 0.31%, fucoidan 0.15%, dihydroxyacetone 6.12% and pure water 91.80%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 23 ℃ and the relative humidity is 45%, the sectional type soluble microneedle solution is filled into a microneedle mould and used for forming a microneedle tip.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45 percent and the drying time of more than 2 hours to obtain the microneedle substrate preparation.
The detection proves that the needle point is obvious in segmentation, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is basically not diffused, as shown in S1 in figure 1.
Example 2
A segmented soluble microneedle solution comprising, in weight percent: 15.23% of GH, 0.12% of histidine, 0.30% of poloxamer, 4.57% of mannitol, 0.61% of fucoidan, 18.27% of dihydroxyacetone and 60.90% of pure water.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 25 ℃ and the relative humidity is 55%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45 percent and the drying time of more than 2 hours to obtain the microneedle substrate preparation.
The detection shows that the needle point is obviously segmented, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is basically not diffused, as shown in S2 in figure 1.
Example 3
A segmented soluble microneedle solution comprising, in weight percent: GH 1.92%, histidine 0.06%, poloxamer 0.10%, mannitol 0.64%, fucoidan 0.26%, dihydroxyacetone 7.66% and purified water 89.36%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 22 ℃ and the relative humidity is 65%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45% and the drying time of more than 2h to obtain the microneedle material.
The detection proves that the needle point is segmented obviously, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is not diffused basically, as shown in S3 in figure 1.
Example 4
A segmented soluble microneedle solution comprising, in weight percent: GH 14.55%, histidine 0.09%, poloxamer 0.27%, mannitol 4.24%, fucoidan 0.55%, dihydroxyacetone 13.64% and pure water 66.66%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 28 ℃ and the relative humidity is 50%, the sectional type soluble microneedle solution is poured into a microneedle mould to form a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45% and the drying time of more than 2h to obtain the microneedle material.
The detection shows that the needle point is obviously segmented, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is not basically diffused, as shown in S4 in figure 1.
Example 5
A segmented soluble microneedle solution comprising, in weight percent: GH6.47%, histidine 0.08%, poloxamer 0.19%, mannitol 2.27%, fucoidan 0.39%, dihydroxyacetone 9.71% and pure water 80.89%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 20 ℃ and the relative humidity is 45%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45 percent and the drying time of more than 2 hours to obtain the microneedle substrate preparation.
The detection shows that the needle point is obviously segmented, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is not basically diffused, as shown in S5 in figure 1.
Example 6
A segmented soluble microneedle solution comprises the following components in percentage by weight: GH 1.92%, histidine 0.06%, poloxamer 0.10%, mannitol 0.64%, fucoidan 0.55%, dihydroxyacetone 7.66% and purified water 89.07%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 22 ℃ and the relative humidity is 65%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle tip.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45% and the drying time of more than 2h to obtain the microneedle material.
The detection shows that the needle point is obviously segmented, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is basically not diffused, as shown in S6 in figure 1.
Example 7
A segmented soluble microneedle solution comprises the following components in percentage by weight: GH 14.55%, histidine 0.09%, poloxamer 0.27%, mannitol 4.24%, fucoidan 0.55%, dihydroxyacetone 7.66% and pure water 72.64%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 28 ℃ and the relative humidity is 50%, the sectional type soluble microneedle solution is poured into a microneedle mould to form a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45 percent and the drying time of more than 2 hours to obtain the microneedle substrate preparation.
The detection shows that the needle point is obviously segmented, the medicine components are gathered on the needle point (within 2/3 of the volume of the needle body), and the medicine on the needle point is not basically diffused, as shown in S7 in figure 1.
Comparative example 1
A segmented soluble microneedle solution comprising, in weight percent: GH7.20%, histidine 0.09%, poloxamer 0.22%, mannitol 2.52% and purified water 89.97%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol and pure water according to the formula ratio, and performing vacuum defoaming to obtain the sectional soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 25 ℃ and the relative humidity is 45%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45 percent and the drying time of more than 2 hours to obtain the microneedle substrate preparation.
The needle tip segmentation is not obvious through detection, and the needle tip medicament diffuses, as shown in D1 in figure 1.
Comparative example 2
A segmented soluble microneedle solution comprising, in weight percent: GH7.20%, histidine 0.11%, poloxamer 0.22%, mannitol 2.52% and purified water 89.95%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol and pure water according to the formula ratio, and carrying out vacuum defoamation to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 25 ℃ and the relative humidity is 45%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle tip.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45 percent and the drying time of more than 2 hours to obtain the microneedle substrate preparation.
Upon detection, the needle tip segmentation was not evident and the needle tip drug diffused, as shown by D2 in fig. 1.
Comparative example 3
A segmented soluble microneedle solution comprising, in weight percent: GH7.20%, histidine 0.05%, poloxamer 0.22%, mannitol 2.52% and pure water 90.01%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol and pure water according to the formula ratio, and performing vacuum defoaming to obtain the sectional soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 25 ℃ and the relative humidity is 45%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle tip.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45% and the drying time of more than 2h to obtain the microneedle material.
The needle tip segmentation is not obvious through detection, and the needle tip medicament diffuses, as shown in D3 in figure 1.
Comparative example 4
A segmented soluble microneedle solution comprising, in weight percent: GH 6.49%, histidine 0.08%, poloxamer 0.19%, mannitol 2.27%, fucoidan 0.10%, dihydroxyacetone 9.74% and pure water 81.13%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming in vacuum to obtain the sectional type soluble microneedle solution.
A method of fabricating segmented soluble microneedles, comprising the steps of:
s1, under the environment that the temperature is 25 ℃ and the relative humidity is 45%, the sectional type soluble microneedle solution is poured into a microneedle mould and used for forming a microneedle point.
S2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, and demolding at the temperature of 25 ℃, the relative humidity of 45% and the drying time of more than 2h to obtain the microneedle material.
Upon detection, the needle tip segmentation was not evident and the needle tip drug diffused, as shown at D4 in fig. 1.
Comparative example 5
A segmented soluble microneedle solution comprising, in weight percent: GH 6.39%, histidine 0.05%, poloxamer 0.19%, mannitol 2.24%, fucoidan 1.60%, dihydroxyacetone 9.59% and pure water 79.94%.
The preparation method of the sectional type soluble microneedle solution comprises the following steps; GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water in the formula amount are mixed and stirred, but the solution viscosity is too large to prepare a uniform mixed solution.
The present invention has been further described with reference to specific embodiments, which are only exemplary and do not limit the scope of the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (10)
1. A segmented soluble microneedle solution comprising the following components: GH. Histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water.
2. The segmented soluble microneedle solution of claim 1 comprising, in weight percent: GH 1.53-15.23%, histidine 0.03-0.12%, poloxamer 0.06-0.30%, mannitol 0.31-4.57%, fucoidin 0.15-0.61%, dihydroxyacetone 6.12-18.27% and pure water 60.90-91.80%.
3. The segmented soluble microneedle solution according to claim 2, wherein said fucoidan is present in an amount of 0.26-0.55%; the dosage of the dihydroxyacetone is 7.66-13.64%.
4. The segmented soluble microneedle solution of claim 3 comprising, in weight percent: GH6.47%, histidine 0.08%, poloxamer 0.19%, mannitol 2.27%, fucoidan 0.39%, dihydroxyacetone 9.71% and pure water 80.89%.
5. A method of preparing a segmented soluble microneedle solution according to any one of claims 1 to 4, comprising the steps of; and uniformly mixing and stirring GH, histidine, poloxamer, mannitol, fucoidin, dihydroxyacetone and pure water according to the formula ratio, and defoaming to obtain the sectional type soluble microneedle solution.
6. Use of the segmented soluble microneedle solution of any one of claims 1-4 or the segmented soluble microneedle solution prepared by the method of claim 5 in the preparation of segmented soluble microneedles.
7. A segmented soluble microneedle, which is prepared from the segmented soluble microneedle solution according to any one of claims 1 to 4 or the segmented soluble microneedle solution prepared by the preparation method according to claim 5.
8. A method of fabricating the segmented soluble microneedle according to claim 7, comprising the steps of:
s1, pouring a soluble microneedle solution into a microneedle mould to form a microneedle tip;
s2, filling the microneedle substrate preparation into the mold filled with the soluble microneedle solution in the step S1, drying and demolding to obtain the microneedle substrate preparation.
9. The method of manufacturing according to claim 8, wherein the method of perfusion in steps S1 and S2 comprises high pressure jetting, centrifugation, vacuum adsorption or self-leveling.
10. The manufacturing method according to claim 8, wherein the environmental conditions for forming the microneedle tip in the step S1 are: the temperature is 20-28 ℃, and the relative humidity is 45-65%; the drying conditions in step S2 are: the temperature is 20-28 ℃, the relative humidity is 30-60%, and the drying time is more than 2 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211137197.4A CN115590810B (en) | 2022-09-19 | 2022-09-19 | Segmented soluble microneedle solution, application, soluble microneedle and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211137197.4A CN115590810B (en) | 2022-09-19 | 2022-09-19 | Segmented soluble microneedle solution, application, soluble microneedle and manufacturing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115590810A true CN115590810A (en) | 2023-01-13 |
| CN115590810B CN115590810B (en) | 2023-04-11 |
Family
ID=84843805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211137197.4A Active CN115590810B (en) | 2022-09-19 | 2022-09-19 | Segmented soluble microneedle solution, application, soluble microneedle and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115590810B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2664323A1 (en) * | 2007-04-16 | 2013-11-20 | Corium International, Inc. | Solvent-cast microneedle arrays containing active |
| CN107050635A (en) * | 2016-12-30 | 2017-08-18 | 向卓林 | A kind of soluble micropin of segmented, microneedle array and preparation method thereof |
| CN108653192A (en) * | 2018-04-23 | 2018-10-16 | 中山大学 | A kind of combined type microneedle patch device and preparation method thereof for controlling growth hormone releasing treatment nanism |
| US20190030309A1 (en) * | 2016-02-11 | 2019-01-31 | Jieun KWON | Method for manufacturing microneedle by using biocompatible polymer |
| CN114010578A (en) * | 2021-11-23 | 2022-02-08 | 中山大学 | Preparation method of fibroin sustained-release microneedle capable of rapidly separating growth hormone |
-
2022
- 2022-09-19 CN CN202211137197.4A patent/CN115590810B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2664323A1 (en) * | 2007-04-16 | 2013-11-20 | Corium International, Inc. | Solvent-cast microneedle arrays containing active |
| US20190030309A1 (en) * | 2016-02-11 | 2019-01-31 | Jieun KWON | Method for manufacturing microneedle by using biocompatible polymer |
| CN107050635A (en) * | 2016-12-30 | 2017-08-18 | 向卓林 | A kind of soluble micropin of segmented, microneedle array and preparation method thereof |
| CN108653192A (en) * | 2018-04-23 | 2018-10-16 | 中山大学 | A kind of combined type microneedle patch device and preparation method thereof for controlling growth hormone releasing treatment nanism |
| CN114010578A (en) * | 2021-11-23 | 2022-02-08 | 中山大学 | Preparation method of fibroin sustained-release microneedle capable of rapidly separating growth hormone |
Non-Patent Citations (1)
| Title |
|---|
| 黄颖聪等: ""微针阵列用于生物大分子药物的递送"" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115590810B (en) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Insulin-loaded silk fibroin microneedles as sustained release system | |
| CN102000020B (en) | Novel micro-needle patch containing degradable polymer and preparation method thereof | |
| KR101610598B1 (en) | FLEXIBLE MICRONEEDLE FOR DENTAL MATERIAL DELIVERY AND THE MANUFACTURING METHOD Of THE SAME | |
| KR101785930B1 (en) | Manufacturing of microneedle systems for inhibition of deformation in moisture environment | |
| EP1781264B1 (en) | Methods for manufacturing delivery devices and devices thereof | |
| CN109045460B (en) | Microneedle patch and preparation method thereof | |
| KR20110005767A (en) | Micro needlearray used porous substrate, and manufacturing method the same | |
| CN110325239A (en) | The manufacturing method of microneedle devices | |
| CN105854172A (en) | Method for manufacturing microstructure body | |
| CN102238943A (en) | Solid microstructure that enables multiple controlled release and method of manufacturing same | |
| JP2015116335A (en) | Percutaneous drug delivery system and method of manufacturing percutaneous drug delivery system | |
| KR101785833B1 (en) | Micro-needles and methof of mamufacture | |
| KR102228571B1 (en) | Drug delivery system for treatment of psychosis or central nervous system diseases | |
| CN109310625A (en) | The outstanding hyaluronic acid microstructured bodies of dissolution characteristics | |
| CN106902453B (en) | A kind of needle body is solvable and the insoluble microneedle preparation method of substrate | |
| CN114146046A (en) | Coated microneedle with multilayer structure, preparation method thereof and microneedle patch comprising coated microneedle | |
| CN114732782B (en) | Needlepoint liquid, microneedle patch, and preparation methods and applications thereof | |
| CN1857730B (en) | Degradable implated medicine release-controlling carrier with micropores and cavities and its preparing process | |
| CN106619480A (en) | Novel polymer micro-needle array and preparation method thereof | |
| JP2013505113A (en) | Implant device for regulating bioactive agent release profile | |
| CN115590810B (en) | Segmented soluble microneedle solution, application, soluble microneedle and manufacturing method thereof | |
| CN112472659B (en) | Sustained-release microneedle patch and preparation method thereof | |
| JP5675820B2 (en) | Implant devices with various bioactive agent loading configurations | |
| CN114177512B (en) | Antibacterial and healing-promoting soluble microneedle patch deposited layer by layer and preparation method thereof | |
| CN113440474B (en) | High-drug-loading high-flexibility porous microneedle material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |